126 related articles for article (PubMed ID: 35367617)
21. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
22. AUSTRALIAN AND NEW ZEALAND STUDY OF PHOTODYNAMIC THERAPY IN CHOROIDAL AMELANOTIC MELANOMA.
O'Day RF; Pejnovic TM; Isaacs T; Muecke JS; Glasson WJ; Campbell WG
Retina; 2020 May; 40(5):972-976. PubMed ID: 30908472
[TBL] [Abstract][Full Text] [Related]
23. Dramatic regression of amelanotic choroidal melanoma with PDT following poor response to brachytherapy.
Tuncer S; Kir N; Shields CL
Ophthalmic Surg Lasers Imaging; 2012 May; 43(3):e38-40. PubMed ID: 22589358
[TBL] [Abstract][Full Text] [Related]
24. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
25. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
[TBL] [Abstract][Full Text] [Related]
26. Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.
Park DG; Jeong S; Noh D; Sagong M
Br J Ophthalmol; 2021 Jun; 105(6):844-849. PubMed ID: 32727733
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
[TBL] [Abstract][Full Text] [Related]
29. Photodynamic Therapy for Retinal Hemangioblastoma: Treatment Outcomes of 17 Consecutive Patients.
Di Nicola M; Williams BK; Hua J; Bekerman VP; Mashayekhi A; Shields JA; Shields CL
Ophthalmol Retina; 2022 Jan; 6(1):80-88. PubMed ID: 33892136
[TBL] [Abstract][Full Text] [Related]
30. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
Arevalo JF; Espinoza JV
Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
[TBL] [Abstract][Full Text] [Related]
31. Half-fluence photodynamic therapy in peripapillary circumscribed choroidal haemangiomas.
Kumar A; Kumar P; Mishra SK; Jhanawar M; Gupta A; Sathagopam S
Int Ophthalmol; 2022 May; 42(5):1605-1612. PubMed ID: 35088358
[TBL] [Abstract][Full Text] [Related]
32. COMPARATIVE EFFECTIVENESS OF PROTON BEAM VERSUS PHOTODYNAMIC THERAPY TO SPARE THE VISION IN CIRCUMSCRIBED CHOROIDAL HEMANGIOMA.
Mathis T; Maschi C; Mosci C; Espensen CA; Rosier L; Favard C; Tick S; Remignon CH; Ligorio P; Bonin N; Gambrelle J; Nguyen AM; Faber C; Meyer L; Mouriaux F; Herault J; Baillif S; Kiilgaard JF; Kodjikian L; Caujolle JP; Salleron J; Thariat J
Retina; 2021 Feb; 41(2):277-286. PubMed ID: 32404844
[TBL] [Abstract][Full Text] [Related]
33. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
34. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
35. Photodynamic therapy for bullous retinal detachment: a single-center experience of case series with a 6-month follow-up study.
Gao T; Qu J; Xiao J; Hu J; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1429-1439. PubMed ID: 29869216
[TBL] [Abstract][Full Text] [Related]
36. Photodynamic therapy for choroidal metastasis in 8 cases.
Kaliki S; Shields CL; Al-Dahmash SA; Mashayekhi A; Shields JA
Ophthalmology; 2012 Jun; 119(6):1218-22. PubMed ID: 22386261
[TBL] [Abstract][Full Text] [Related]
37. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.
Park YJ; Kim YK; Park KH; Woo SJ
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221
[TBL] [Abstract][Full Text] [Related]
39. PHOTODYNAMIC THERAPY FOR CHOROIDAL NEVUS WITH SUBFOVEAL FLUID.
Pointdujour-Lim R; Mashayekhi A; Shields JA; Shields CL
Retina; 2017 Apr; 37(4):718-723. PubMed ID: 27433882
[TBL] [Abstract][Full Text] [Related]
40. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
